Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.60 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28624684 | 1.00 | GPR84 (0.60) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| 1,6-Hexanediol SCHEMBL28628065 | 1.00 | GPR84 (0.60) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL5575807 | 1.00 | GPR84 (0.60) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL7554526 | 1.00 | GPR84 (0.60) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL2839590 | 1.00 | GPR84 (0.60) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL8411317 | 1.00 | GPR84 (0.60) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL1479946 | 1.00 | GPR84 (0.60) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL5575804 | 1.00 | GPR84 (0.60) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL2011125 | 1.00 | GPR84 (0.60) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL6924277 | 1.00 | GPR84 (0.60) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7009052-B2 | Sulfonamide derivatives | WARNER LAMBERT COMPANY LLC (US) | 2006-03-07 | — | — | US | claimed |
| US-20050004367-A1 | Sulfonamide derivatives | DU DANIEL Y (US) | 2005-01-06 | — | — | US | claimed |
| EP-4623104-A1 | METHODS FOR DETECTING DIASTATIC YEAST CONTAMINANTS | Invisible Sentinel, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-4623108-A2 | METHODS FOR DETECTING ALICYCLOBACILLUS CONTAMINANTS | Invisible Sentinel, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| CN-119630679-A | IP5 substituted compounds | 萨尼菲特治疗有限公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2024137744-A9 | METHODS FOR DETECTING ALICYCLOBACILLUS CONTAMINANTS | Invisible Sentinel, Inc. (US) | 2025-02-06 | — | — | WO | disclosed |
| WO-2024137376-A1 | METHODS FOR DETECTING DIASTATIC YEAST CONTAMINANTS | Invisible Sentinel, Inc. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024137744-A2 | METHODS FOR DETECTING ALICYCLOBACILLUS CONTAMINANTS | Invisible Sentinel, Inc. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240173320-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2024-05-30 | — | — | US | disclosed |
| US-11407721-B2 | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2021-07-15 | — | — | US | disclosed |
| EP-0602209-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| EP-0569487-A4 | — | — | 1994-04-27 | — | — | EP | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| EP-0569487-A1 | ENDOTHELIN CONVERTING ENZYME INHIBITORS | ABBOTT LABORATORIES (US) | 1993-11-18 | — | — | EP | disclosed |
| WO-1992013545-A1 | ENDOTHELIN CONVERTING ENZYME INHIBITORS | ABBOTT LABORATORIES (US) | 1992-08-20 | — | — | WO | disclosed |
| EP-0450097-A1 | BENZOHETEROCYCLIC COMPOUNDS. | OTSUKA PHARMA CO LTD (JP) | 1991-10-09 | — | — | EP | disclosed |
| WO-1991005549-A1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | WO | disclosed |
| US-4251422-A | Coating compositions containing polymers with isocyano groups and alkylboranes | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-02-17 | — | — | US | disclosed |
| US-4251421-A | CROSSLINKABLE FILM-FORMING PRIMERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004367-A1 | Sulfonamide derivatives | AR, SULT2A1, SHBG | GPR84 246/4885FFAR1 1158/4885FFAR4 743/4885 |
| US-20240173320-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | GPR84 2967/4885FFAR1 4405/4885FFAR4 4272/4885 |
| US-11407721-B2 | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer | MDM2, TP53, MDM4 | GPR84 2974/4885FFAR1 4272/4885FFAR4 4674/4885 |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | GPR84 2967/4885FFAR1 4405/4885FFAR4 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.